FDA Approves Tzield for Pediatric Stage 3 Type I Diabetes
The FDA has approved Tzield (teplizumab) for delaying insulin loss in pediatric patients with Stage 3 Type I diabetes.
Therapeutic Area
Therapeutic area intelligence for Type I Diabetes with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.